HK1083767A1 - Combined use of a fibrate and orlistat for the treatment of obesity - Google Patents

Combined use of a fibrate and orlistat for the treatment of obesity

Info

Publication number
HK1083767A1
HK1083767A1 HK06106181A HK06106181A HK1083767A1 HK 1083767 A1 HK1083767 A1 HK 1083767A1 HK 06106181 A HK06106181 A HK 06106181A HK 06106181 A HK06106181 A HK 06106181A HK 1083767 A1 HK1083767 A1 HK 1083767A1
Authority
HK
Hong Kong
Prior art keywords
fibrate
orlistat
obesity
treatment
combined use
Prior art date
Application number
HK06106181A
Other languages
English (en)
Inventor
Edgar Alan
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of HK1083767A1 publication Critical patent/HK1083767A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
HK06106181A 2003-03-13 2006-05-29 Combined use of a fibrate and orlistat for the treatment of obesity HK1083767A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290625A EP1457206A1 (de) 2003-03-13 2003-03-13 Kombinierte Verwendung von einem Fibrat und von Orlistat zur Behandlung von Obesitas
PCT/EP2004/004010 WO2004080450A2 (en) 2003-03-13 2004-03-12 Combined use of a fibrate and orlistat for the treatment of obesity

Publications (1)

Publication Number Publication Date
HK1083767A1 true HK1083767A1 (en) 2006-07-14

Family

ID=32749013

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06106181A HK1083767A1 (en) 2003-03-13 2006-05-29 Combined use of a fibrate and orlistat for the treatment of obesity

Country Status (19)

Country Link
US (1) US20070078179A1 (de)
EP (2) EP1457206A1 (de)
JP (1) JP4928256B2 (de)
CN (1) CN100562313C (de)
AT (1) ATE384520T1 (de)
AU (1) AU2004218938B2 (de)
BR (1) BRPI0408322A (de)
CA (1) CA2518205C (de)
DE (1) DE602004011486T2 (de)
DK (1) DK1601352T3 (de)
EA (1) EA009127B1 (de)
ES (1) ES2300750T3 (de)
HK (1) HK1083767A1 (de)
IL (1) IL170519A (de)
MX (1) MXPA05009718A (de)
NO (1) NO20054700L (de)
PT (1) PT1601352E (de)
WO (1) WO2004080450A2 (de)
ZA (1) ZA200507227B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
EP2625968A1 (de) * 2007-09-12 2013-08-14 Københavns Universitet Zusammensetzungen und methoden zur verstärkung der hungerunterdrückung und zum reduzieren der verdaulichkeit der nichtfettenergiesättigung
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
CA2795320C (en) 2010-04-12 2019-01-22 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
MX336980B (es) 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
CN104870018A (zh) * 2012-12-21 2015-08-26 默克专利股份有限公司 具有改善的活性物质的释放作为药物制剂中载体的碱式碳酸镁

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
TW438784B (en) * 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
AU784722B2 (en) * 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1424070A1 (de) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels

Also Published As

Publication number Publication date
CN100562313C (zh) 2009-11-25
US20070078179A1 (en) 2007-04-05
AU2004218938A1 (en) 2004-09-23
NO20054700L (no) 2005-10-12
EA009127B1 (ru) 2007-10-26
AU2004218938B2 (en) 2009-04-09
BRPI0408322A (pt) 2006-03-14
ATE384520T1 (de) 2008-02-15
EP1457206A1 (de) 2004-09-15
IL170519A (en) 2010-12-30
EP1601352B1 (de) 2008-01-23
IL170519A0 (en) 2006-10-05
DE602004011486T2 (de) 2009-01-15
CA2518205A1 (en) 2004-09-23
EA200501259A1 (ru) 2006-02-24
DK1601352T3 (da) 2008-05-13
DE602004011486D1 (de) 2008-03-13
EP1601352A2 (de) 2005-12-07
WO2004080450A3 (en) 2005-02-24
MXPA05009718A (es) 2005-10-18
WO2004080450A2 (en) 2004-09-23
CN1826108A (zh) 2006-08-30
PT1601352E (pt) 2008-04-07
CA2518205C (en) 2012-05-08
ES2300750T3 (es) 2008-06-16
JP2006520365A (ja) 2006-09-07
JP4928256B2 (ja) 2012-05-09
ZA200507227B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
EP1534074A4 (de) Kombinationstherapie zur behandlung von fettleibigkeit
IL188249A0 (en) Cephalosporin related compounds for use in therapy
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
IL164599A0 (en) Combination therapy for the treatment of cancer
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
AU2003258305A8 (en) Combination therapy for treatment of fibrotic disorders
ZA200500719B (en) The use of the combination of ciclesonide and antihitamines for the treatment of allergic rhinitis.
AU2003300791A1 (en) Combination therapy for the treatment of pain
IL159887A0 (en) Combination therapy for the treatment of cancer
HK1083767A1 (en) Combined use of a fibrate and orlistat for the treatment of obesity
HUP0400024A2 (hu) Neoplasztikus betegségek kezelésére szolgáló gyógyszerkombinációk
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
PL386471A1 (pl) Związki indolonu użyteczne w leczeniu upośledzenia poznawczego
GB0211414D0 (en) Treatment of respiratory disorders
GB0224330D0 (en) Treatment of respiratory disorders
GB0324283D0 (en) Therapeutic agents for the treatment of bone disorders
GB0305343D0 (en) Therapeutic agents for the treatment of bone disorders
GB0317241D0 (en) Therapeutic agents for the treatment of bone disorders
ZA200408071B (en) Combination therapy for the treatment of cancer.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130312